CorMedix (CRMD) Net Income towards Common Stockholders (2010 - 2025)

CorMedix (CRMD) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$11.8 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 187.47% year-over-year to -$11.8 million; the trailing twelve-month figure through Dec 2025 stood at $139.3 million (up 876.67% YoY), and the FY2025 full-year result was $137.3 million, up 865.52% from the prior year.
• Net Income towards Common Stockholders retreated to -$11.8 million in Q4 2025, from $108.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $108.5 million in Q3 2025 to a low of -$14.8 million in Q4 2023.
• A 5-year average of $4.3 million and a median of -$4.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders plunged 250.96% in 2023 and jumped 4001.2% in 2025, its largest moves.
• Tracing CRMD's Net Income towards Common Stockholders over 5 years: stood at -$9.7 million in 2021, then grew by 15.08% to -$8.2 million in 2022, then tumbled by 79.73% to -$14.8 million in 2023, then jumped by 191.26% to $13.5 million in 2024, then slumped by 187.47% to -$11.8 million in 2025.
• Business Quant data shows CRMD's Net Income towards Common Stockholders at -$11.8 million in Q4 2025, $108.5 million in Q3 2025, and $21.9 million in Q2 2025.